Ikarian Capital »

Enliven Therapeutics shares owned by Ikarian Capital

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2024-09-30 $13M 500k 25.54
2024-06-30 $14M 587k 23.37

More positions owned by Ikarian Capital

Vertex Pharmaceuticals Incorporated Put Option (VRTX)
Amgen Call Option (AMGN)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Tarsus Pharmaceuticals (TARS)
Beigene Sponsored Adr Call Option (BGNE)
Anaptysbio Inc Common Put Option (ANAB)
Crinetics Pharmaceuticals In (CRNX)
Celldex Therapeutics Com New Put Option (CLDX)
Soleno Therapeutics Call Option (SLNO)
Janux Therapeutics Put Option (JANX)
Biohaven Put Option (BHVN)
Miragen Therapeutics Call Option (VRDN)
Immunovant Call Option (IMVT)
Capricor Therapeutics Com New Put Option (CAPR)
Arcus Biosciences Incorporated Call Option (RCUS)

View all positions for Ikarian Capital

Top funds holding Enliven Therapeutics

OrbiMed Advisors
Commodore Capital
VR Adviser
Fairmount Funds Management
BlackRock
BlackRock
Vanguard Group
5AM Venture Management
Citadel Advisors
RA Capital Management
Pictet Asset Management Holding SA
Woodline Partners
Soleus Capital Management
Geode Capital Management
Henderson Group

View all funds holding Enliven Therapeutics